Author:
Yamaguchi Junpei,Yokoyama Yukihiro,Fujii Tsutomu,Yamada Suguru,Takami Hideki,Kawashima Hiroki,Ohno Eizaburo,Ishikawa Takuya,Maeda Osamu,Ogawa Hiroshi,Kodera Yasuhiro,Nagino Masato,Ebata Tomoki
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference35 articles.
1. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States;Rahib;Cancer Res,2014
2. Therapeutic developments in pancreatic cancer: current and future perspectives;Neoptolemos;Nat Rev Gastroenterol Hepatol,2018
3. Pancreatic cancer;Kleeff;Nat Rev Dis Primers,2016
4. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial;Neoptolemos;Lancet,2017
5. CONKO-005: adjuvantchemotherapywith gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial;Sinn;J Clin Oncol,2017
Cited by
60 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献